Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

What was reported

DURHAM, N.C., June 10, 2026 – Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced positive top-line interim results for the V012 Phase 3 study of the acellular tissue engineered vessel (ATEV) in female patients for dialysis access.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Jun 10, 2026 · Open the source ↗

What the evidence supports

Humacyte furnished a press release to the SEC (Form 8-K, Item 8.01) about a company announcement. It shows what the company chose to disclose on that date.

What remains unknown

Claims in the release are the company's own and have not been independently verified. Furnishing a document to the SEC does not mean the SEC reviewed or endorsed it.

Source passages

Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.

Press release headlineHumacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access PatientsU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Jun 10, 2026 · Open the source ↗

Press release lead paragraphDURHAM, N.C., June 10, 2026 – Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced positive top-line interim results for the V012 Phase 3 study of the acellular tissue engineered vessel (ATEV) in female patients for dialysis access.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Jun 10, 2026 · Open the source ↗

Revision history

1. Revision 1 · Oct 28, 2026, 20:52 UTC

   Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

Spotted an error? Tell us. Corrections are published, never silent: see all corrections.